Hospira Recalls Furosemide Injection Vials Due to Sterility Concerns
Hospira is recalling 63,900 vials of Furosemide Injection USP because a loose crimp on the vial cap may compromise sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric for potential serious, reversible health consequences.
Plain-English summary
Hospira, Inc. is recalling 63,900 vials of Furosemide Injection USP (10 mg/mL), 4 mL in 5 mL Fliptop Vial, NDC 0409-6102-04. The recall was initiated due to a lack of assurance of sterility, which may be caused by a possible loose crimp applied to the fliptop vial.
The affected product is a prescription-only medication intended for intramuscular or intravenous administration. The recall covers product distributed nationwide. The specific lot code associated with this recall is 18-099-DK.
Healthcare providers and patients should check their inventory for the specific NDC and lot code listed above. If the product is found, it should be quarantined and not administered until further notice. Consumers should contact their healthcare provider or pharmacist for guidance on alternative treatments or replacement products.
The recalled product
- Product
- FUROSEMIDE (FUROSEMIDE)
- Brand
- FUROSEMIDE
- Manufacturer
- Hospira, Inc.
- Category
- Drug — Injection
- Affected units
- 63,900
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 18-099-DK
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · FUROSEMIDE
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- HighFurosemide tablets recalled over the presence of a foreign substance
FDA (Drugs) · 2026-01-28
- ModerateRoxane Recalls Furosemide Tablets Due to Unusually Thick Tablet Report
FDA (Drugs) · 2017-02-01
- ModerateBoehringer Ingelheim Roxane Recalls Furosemide Tablets Due to CGMP Deviations
FDA (Drugs) · 2015-10-21
- ModerateBoehringer Ingelheim Roxane Recalls Furosemide Tablets Due to Manufacturing Error
FDA (Drugs) · 2015-10-21
Same manufacturer · Hospira, Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29